Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 18, 24 | 0.12 Increased by +129.27% | -0.34 Increased by +135.29% |
| Nov 14, 23 | -0.24 Increased by +42.86% | -0.33 Increased by +27.27% |
| Aug 14, 23 | -0.27 Increased by +55% | -0.37 Increased by +27.03% |
| May 11, 23 | -0.28 Decreased by -12% | -0.37 Increased by +24.32% |
| Mar 23, 23 | -0.41 Increased by +21.15% | -0.27 Decreased by -51.85% |
| Nov 14, 22 | -0.42 Increased by +23.64% | -0.1 Decreased by -320% |
| Aug 11, 22 | -0.6 Decreased by -30.43% | -0.39 Decreased by -53.85% |
| May 12, 22 | -0.25 Increased by +44.44% | -0.19 Decreased by -31.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 10.04 M Increased by +20.03% | -11.72 M Increased by +7.8% | Decreased by -116.72% Increased by +23.19% |
| Jun 30, 23 | 8.59 M Increased by +62.38% | -13.16 M Increased by +27.31% | Decreased by -153.1% Increased by +55.23% |
| Mar 31, 23 | 9.39 M Decreased by -31.12% | -11.01 M Decreased by -46.27% | Decreased by -117.29% Decreased by -112.37% |
| Dec 31, 22 | 2.78 M Decreased by -38.72% | -18.86 M Decreased by -24.38% | Decreased by -679.54% Decreased by -102.96% |
| Sep 30, 22 | 8.37 M Decreased by -1.75% | -12.71 M Increased by +5.78% | Decreased by -151.95% Increased by +4.1% |
| Jun 30, 22 | 5.29 M Decreased by -26.43% | -18.1 M Decreased by -64.09% | Decreased by -341.99% Decreased by -123.04% |
| Mar 31, 22 | 13.63 M Increased by +325.37% | -7.53 M Increased by +29.28% | Decreased by -55.23% Increased by +83.37% |
| Dec 31, 21 | 4.53 M Decreased by -19.72% | -15.17 M Decreased by -139.15% | Decreased by -334.81% Decreased by -197.91% |
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.